Dechert Advises Biomunex Pharmaceuticals in Strategic License and Co-Development Agreement with Onward Therapeutics and Series A Fundraising
Dechert advised Biomunex Pharmaceuticals, a French biopharmaceutical company, in connection with a strategic exclusive worldwide license and co-development agreement with Onward Therapeutics SA for a proprietary bispecific antibody program, as well as in its Series A funding round. Onward Therapeutics, a Swiss development stage oncology company, will also invest in Biomunex, participating in the Series A.
The Dechert team advising Biomunex includes national partner Marie Fillon and associate Louis de Chezelles on IP and licensing aspects and partner Anne-Charlotte Rivière and associate Johann Gandilhon on corporate aspects.
About Dechert
Dechert is a leading global law firm with 26 offices around the world. We advise on matters and transactions of the greatest complexity, bringing energy, creativity and efficient management of legal issues to deliver commercial and practical advice for clients.
